Canada · Delayed Price · Currency is CAD NexgenRx Statistics
Total Valuation
NexgenRx has a market cap or net worth of CAD 28.45 million. The enterprise value is 28.40 million.
| Market Cap | 28.45M |
| Enterprise Value | 28.40M |
Important Dates
The next estimated earnings date is Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | Aug 25, 2025 |
Share Statistics
NexgenRx has 71.12 million shares outstanding. The number of shares has increased by 12.29% in one year.
| Current Share Class | 71.12M |
| Shares Outstanding | 71.12M |
| Shares Change (YoY) | +12.29% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 37.18% |
| Owned by Institutions (%) | n/a |
| Float | 44.38M |
Valuation Ratios
The trailing PE ratio is 39.61.
| PE Ratio | 39.61 |
| Forward PE | n/a |
| PS Ratio | 1.66 |
| PB Ratio | 3.52 |
| P/TBV Ratio | 8.71 |
| P/FCF Ratio | 16.52 |
| P/OCF Ratio | 13.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.03, with an EV/FCF ratio of 16.50.
| EV / Earnings | 35.30 |
| EV / Sales | 1.65 |
| EV / EBITDA | 16.03 |
| EV / EBIT | 18.66 |
| EV / FCF | 16.50 |
Financial Position
The company has a current ratio of 1.10, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.10 |
| Quick Ratio | 0.10 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.25 |
| Debt / FCF | 0.25 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 12.52% and return on invested capital (ROIC) is 11.23%.
| Return on Equity (ROE) | 12.52% |
| Return on Assets (ROA) | 2.87% |
| Return on Invested Capital (ROIC) | 11.23% |
| Return on Capital Employed (ROCE) | 17.95% |
| Revenue Per Employee | 858,347 |
| Profits Per Employee | 40,221 |
| Employee Count | 20 |
| Asset Turnover | 0.52 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NexgenRx has paid 412,150 in taxes.
| Income Tax | 412,150 |
| Effective Tax Rate | 29.14% |
Stock Price Statistics
The stock price has increased by +26.67% in the last 52 weeks. The beta is 0.53, so NexgenRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +26.67% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.32 |
| Relative Strength Index (RSI) | 57.20 |
| Average Volume (20 Days) | 2,165 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NexgenRx had revenue of CAD 17.17 million and earned 804,426 in profits. Earnings per share was 0.01.
| Revenue | 17.17M |
| Gross Profit | 13.72M |
| Operating Income | 1.52M |
| Pretax Income | 1.41M |
| Net Income | 804,426 |
| EBITDA | 1.66M |
| EBIT | 1.52M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 2.13 million in cash and 437,177 in debt, giving a net cash position of 1.70 million or 0.02 per share.
| Cash & Cash Equivalents | 2.13M |
| Total Debt | 437,177 |
| Net Cash | 1.70M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 8.09M |
| Book Value Per Share | 0.09 |
| Working Capital | 2.83M |
Cash Flow
In the last 12 months, operating cash flow was 2.05 million and capital expenditures -328,706, giving a free cash flow of 1.72 million.
| Operating Cash Flow | 2.05M |
| Capital Expenditures | -328,706 |
| Free Cash Flow | 1.72M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 79.94%, with operating and profit margins of 8.87% and 5.84%.
| Gross Margin | 79.94% |
| Operating Margin | 8.87% |
| Pretax Margin | 8.24% |
| Profit Margin | 5.84% |
| EBITDA Margin | 9.69% |
| EBIT Margin | 8.87% |
| FCF Margin | 10.03% |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 2.50%.
| Dividend Per Share | 0.01 |
| Dividend Yield | 2.50% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 90.70% |
| Buyback Yield | -12.29% |
| Shareholder Yield | -9.66% |
| Earnings Yield | 2.83% |
| FCF Yield | 6.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NexgenRx has an Altman Z-Score of 1.06 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.06 |
| Piotroski F-Score | 7 |